Systemic Sclerosis

You have full text access to this OnlineOpen article

Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population

  1. Ikue Ito1,
  2. Yasushi Kawaguchi2,
  3. Aya Kawasaki1,
  4. Minoru Hasegawa3,
  5. Jun Ohashi1,
  6. Koki Hikami1,
  7. Manabu Kawamoto2,
  8. Manabu Fujimoto3,
  9. Kazuhiko Takehara3,†,
  10. Shinichi Sato4,
  11. Masako Hara2,
  12. Naoyuki Tsuchiya1,*

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24600

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 6, pages 1845–1850, June 2009

Additional Information

How to Cite

Ito, I., Kawaguchi, Y., Kawasaki, A., Hasegawa, M., Ohashi, J., Hikami, K., Kawamoto, M., Fujimoto, M., Takehara, K., Sato, S., Hara, M. and Tsuchiya, N. (2009), Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis & Rheumatism, 60: 1845–1850. doi: 10.1002/art.24600

Author Information

  1. 1

    University of Tsukuba, Tsukuba, Japan

  2. 2

    Tokyo Women's Medical University, Tokyo, Japan

  3. 3

    Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

  4. 4

    Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

  1. †

    Dr. Takehara has received consulting fees from Benesis Corporation (more than $10,000).

*Doctoral Program in Life System Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 18 MAR 2009
  4. Manuscript Received: 17 SEP 2008

Funded by

  • Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science, Health, and Labour Sciences Research grants from the Ministry of Health, Labour, and Welfare of Japan
  • Japan Rheumatism Foundation
  • Naito Foundation
  • Mitsubishi Pharma Research Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

REFERENCES

  • 1
    Mayes MD, Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther 2007; 9 Suppl 2: S5.
  • 2
    Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58: 1465–74.
    Direct Link:
  • 3
    Kyogoku C, Tsuchiya N. A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun 2007; 8: 445–55.
  • 4
    Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550–5.
  • 5
    Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007; 104: 6758–63.
  • 6
    Ferreiro-Neira I, Calaza M, Alonso-Perez E, Marchini M, Scorza R, Sebastiani GD, et al. Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun 2007; 8: 429–38.
  • 7
    Kawasaki A, Kyogoku C, Ohashi J, Miyashita R, Hikami K, Kusaoi M, et al. Association of IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: support for a crucial role of intron 1 polymorphisms. Arthritis Rheum 2008; 58: 826–34.
    Direct Link:
  • 8
    Kelly JA, Kelley JM, Kaufman KM, Kilpatrick J, Bruner GR, Merrill JT, et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun 2008; 9: 187–94.
  • 9
    Dieude P, Guedj M, Wipff J, Avouac J, Fajardy I, Diot E, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009; 60: 225–33.
    Direct Link:
  • 10
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 11
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5.
  • 12
    Ohashi J, Yamamoto S, Tsuchiya N, Hatta Y, Komata T, Matsushita M, et al. Comparison of statistical power between 2 × 2 allele frequency and allele positivity tables in case-control studies of complex disease genes. Ann Hum Genet 2001; 65 (Part 2): 197–206.
  • 13
    Hugle T, Gratzl S, Daikeler T, Frey D, Tyndall A, Walker UA. Sclerosing skin disorders in association with multiple sclerosis: coincidence, underlying autoimmune pathology, or interferon induced? Ann Rheum Dis 2009; 68: 47–50.
  • 14
    Lai MC, Lin RI, Huang SY, Tsai CW, Tarn WY. A human importin-β family protein, transportin-SR2, interacts with the phosphorylated RS domain of SR proteins. J Biol Chem 2000; 275: 7950–7.
  • 15
    Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, et al. Induction of interferon-α by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-α activity with lung fibrosis. Arthritis Rheum 2008; 58: 2163–73.
    Direct Link:
View Full Article (HTML) Get PDF (132K)